Impact of platinum-based chemotherapy and CTLA-4 inhibition on acquired resistance to first-line anti-PD-1/PD-L1 agents in non-small cell lung cancer: a systematic review and reconstructed individual patient data analysis.

ABSTRACT:

Background

Acquired resistance is defined as disease progression following an initial response to immune checkpoint inhibitors (ICI). The impact of adding platinum-based chemotherapy (PCT) or anti-CTLA-4 agents to PD-(L)-1 inhibitors on acquired resistance is currently unknown.

Methods

Systematic research by January 31, 2025 identified randomized clinical trials (RCTs) evaluating first-line ICI as monotherapy (mono-ICI) or in combination with PCT (mono-ICI + PCT), CTLA-4 inhibitors (combo-ICI), or both (combo-ICI + PCT) in metastatic non-small-cell lung cancer (NSCLC). RCTs reporting duration of response (DoR) data were eligible. Acquired resistance rates at 6 and 12 months were estimated from DoR curves. Aggregate data based on type of regimens were reported with risk ratio

SUBMITTER: Oresti S 

PROVIDER: S-EPMC12441679 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature